the recently approved version of til therapy developed by iovance biotherapeutics, a biotechnology company in california, us, uses immune cells to fight melanoma. while til therapy isn’t new, this particular cellular therapy is the first to be approved to treat solid tumours and was given fast-track approval because of the promising results from clinical trials.
the treatment works because when tumours grow, they contain tissue and other cells, including immune cells. those specific immune cells within the tumour can fight off cancer cells, but there are often not enough of them to win the battle. the new til therapy harvests these cancer-fighting cells from the tumour, multiplies them into billions, and then injects them back into the tumour so that there are more of them, giving them a better chance at shrinking tumours and getting rid of cancer cells.
the results from clinical trials examining the efficacy of the drug found that it worked for as many as 50 per cent of people in reducing disease progression and death, with 20 per cent reaching complete remission from the treatment alone.
while the treatment is still on its way into the hands of real patients, it shows great promise in tumour reduction in melanoma that has spread to other parts of the body, as well as other tumour-related cancers, including colon, lung, head, and bladder cancer.